Based on the analysis of Pfizer's profitability, liquidity, and operating efficiency, Pfizer Inc is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At present, Pfizer's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 28.9 B, whereas Property Plant And Equipment Net is forecasted to decline to about 11.3 B. Key indicators impacting Pfizer's financial strength include:
The essential information of the day-to-day investment outlook for Pfizer includes many different criteria found on its balance sheet. An individual investor should monitor Pfizer's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pfizer.
Cash And Equivalents
1.81 Billion
Pfizer
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Dividends Paid
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Stock Based Compensation
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Total Cashflows From Investing Activities
Change To Account Receivables
Investments
Change Receivables
Net Borrowings
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Operating Activities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Short Term Debt
Intangible Assets
Property Plant Equipment
Accounts Payable
Accumulated Other Comprehensive Income
Common Stock Total Equity
Short Term Investments
Capital Stock
Common Stock
Other Liab
Other Assets
Long Term Debt
Good Will
Treasury Stock
Current Deferred Revenue
Preferred Stock Total Equity
Net Tangible Assets
Total Permanent Equity
Noncontrolling Interest In Consolidated Entity
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Additional Paid In Capital
Deferred Long Term Liab
Long Term Investments
Non Current Liabilities Other
Short Long Term Debt
Cash And Equivalents
Net Invested Capital
Net Working Capital
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Research Development
Net Income Applicable To Common Shares
Minority Interest
Discontinued Operations
Net Income From Continuing Ops
Non Recurring
Selling And Marketing Expenses
Non Operating Income Net Other
Tax Provision
Interest Income
Extraordinary Items
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Pfizer Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Pfizer's financial statements are interrelated, with each one affecting the others. For example, an increase in Pfizer's assets may result in an increase in income on the income statement.
Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.
Pfizer Stock Summary
Pfizer competes with Johnson Johnson, Small Cap, Freedom Holding, Gfl Environmental, and Growth Fund. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people.
Foreign Associates
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Pfizer's current stock value. Our valuation model uses many indicators to compare Pfizer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pfizer competition to find correlations between indicators driving Pfizer's intrinsic value. More Info.
Pfizer Inc is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.73 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pfizer Inc is roughly 1.37 . At present, Pfizer's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pfizer by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Pfizer Inc Systematic Risk
Pfizer's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pfizer volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Pfizer Inc correlated with the market. If Beta is less than 0 Pfizer generally moves in the opposite direction as compared to the market. If Pfizer Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pfizer Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pfizer is generally in the same direction as the market. If Beta > 1 Pfizer moves generally in the same direction as, but more than the movement of the benchmark.
Pfizer Thematic Clasifications
Pfizer Inc is part of Robots And Drones investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Cross-sector firms and funds that develop or invest in technology that can replicate repetitive human actions. Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years
This theme covers Cross-sector firms and funds that develop or invest in technology that can replicate repetitive human actions. Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years. Get More Thematic Ideas
Today, most investors in Pfizer Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pfizer's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Pfizer growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(0.78)
At present, Pfizer's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Pfizer November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Pfizer help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pfizer Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pfizer Inc based on widely used predictive technical indicators. In general, we focus on analyzing Pfizer Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pfizer's daily price indicators and compare them against related drivers.
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.